- Home
- HYFM vs PULM Comparison
HYFM vs PULM Comparison
Compare HYFM & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | PULM |
|---|---|---|
| Founded | 1977 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 9.4M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HYFM | PULM |
|---|---|---|
| Price | $1.37 | $2.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.0K | 7.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,288,000.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.57 | $134.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $1.35 | $2.15 |
| 52 Week High | $5.80 | $9.47 |
Technical Indicators
Market Signals| Indicator | HYFM | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 57.36 |
| Support Level | $1.40 | $2.36 |
| Resistance Level | $1.48 | $2.53 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 78.98 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).